Whole-Genome Doubling: A Macro-Evolutionary Step in Cancer

What Doubling Does for a Tumour

With four copies of each gene instead of two, a cell can tolerate subsequent loss-of-function mutations and chromosome losses that would otherwise be lethal. Whole-genome doubling therefore acts as a buffer that permits greater downstream genomic instability.

It also provides raw material for copy-number evolution, and doubled genomes tend to keep losing chromosomes gradually toward a near-triploid state.

Associations and Prerequisites

Whole-genome doubling is strongly associated with TP53 mutation, which removes a barrier to proliferating with an abnormal chromosome number. However, a large fraction of doubled tumours are TP53 wild-type, often with defects in the E2F-mediated G1 arrest instead.

Its frequency varies by tumour lineage and correlates with proliferation rate, and it independently predicts increased morbidity in several cancer types.

How It Is Detected

Whole-genome doubling is inferred, not measured directly. Algorithms examine the distribution of allele-specific copy-number states and the fraction of the genome showing major-allele counts of two or more to decide whether a doubling has occurred.

Timing analyses can place the event relative to other mutations. Whether a doubling is truncal (in all tumour cells) or subclonal carries different prognostic weight, with subclonal doubling linked to earlier relapse in lung cancer.

Does It Change Treatment?

Whole-genome doubling is not itself a treatment target, and no therapy is selected on doubling status alone. Its value is prognostic — it independently predicts poorer outcomes in many cancers — and mechanistic, since a doubled, unstable genome is the backdrop against which copy-number-driven resistance evolves.

Research is testing whether doubled tumours have exploitable vulnerabilities, for example dependence on the spindle-assembly checkpoint or on specific mitotic motor proteins to tolerate their abnormal chromosome number. These are laboratory-stage ideas, not current options.

Key Takeaways

• ·Whole-genome doubling duplicates the entire chromosome set in one event, buffering later losses.
• ·It is associated with TP53 loss and with poorer prognosis across many cancer types.
• ·It is inferred from allele-specific copy-number patterns, and truncal versus subclonal timing matters.